WALTHAM, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced a poster presentation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) at ENDO 2017: The Endocrine Society’s 99th Annual Meeting & Expo at 1 p.m. ET on April 2, 2017 at the Orange County Convention Center in Orlando, Florida.
The Acro-TSQ is a novel tool that assesses acromegaly-specific, patient-reported outcomes (PRO) related to medical treatment, including mode of administration. Six questionnaire items focus on acromegaly symptoms, including symptom bother and interference. Results from these symptom items using data from a recent validation study were examined to more fully understand the unmet needs of patients with acromegaly.
“ENDO provides us with a great opportunity to educate the scientific community about Chiasma,” said Dr. Bill Ludlam, senior vice president, clinical development and medical affairs for Chiasma. “This is one of the most important conferences in the field of endocrinology, and we are excited to again participate.”
Patients with acromegaly continue to experience symptoms despite receiving somatostatin receptor ligand (SRL) injections. The Acro-TSQ has been developed to measure the patient burden with currently administered acromegaly therapies, particularly depot injections. The tool is currently being used in Chiasma’s MPOWERED® phase 3 study, which assesses octreotide capsules versus injectable SRLs in patients with acromegaly.
Details for the poster presentation are:
Title: "Evaluation of Acromegaly Symptoms from the Newly Developed Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ): A Prospective Patient-Reported Outcome Study"
Time: 1-3 p.m. ET
Date: Sunday, April 2, 2017
Location: West Hall B, Expo Hall, Orange County Convention Center, Orlando, Florida
For more information on Chiasma’s poster presentation at ENDO 2017, please visit: https://plan.core-apps.com/tristar_endo17/abstract/f7e437ee5c2d999047a03154444f2b75.
Acromegaly is most commonly caused by a benign tumor of the pituitary gland, which produces too much growth hormone (GH), ultimately leading to significant health problems and early death if untreated. There are an estimated 69,000 individuals with acromegaly worldwide. In 13 studies of acromegaly prevalence since 1980, an average of approximately 75 cases per million was determined, suggesting roughly 24,000 individuals with acromegaly in the United States. Because symptoms often develop slowly, diagnosis may be delayed by years or decades, making it difficult to determine the total number of people with the disease.
Common features of acromegaly are facial coarsening, intense headaches, joint pain, impaired vision and enlargement of the hands, feet, tongue and internal organs. Serious health conditions associated with the progression of acromegaly include type 2 diabetes, hypertension, respiratory disorders and cardiac and cerebrovascular disease.
Current treatment options include surgery to remove the pituitary tumor, radiation therapy which destroys any lingering tumor cells, and/or medical treatment in cases where these approaches are not possible or fully effective. Today's medical treatments include dopamine agonists, GH antagonists, and injectable somatostatin analogs, which are the current standard of care.
Chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. The company is conducting an international Phase 3 clinical trial of octreotide capsules (conditionally trade-named “Mycapssa®”) for the maintenance treatment of adult acromegaly patients to support a potential submission of a Marketing Authorization Application to the European Medicines Agency. Chiasma received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on April 15, 2016 regarding its New Drug Application (NDA) for Mycapssa in the United States. Chiasma is headquartered in the United States with a wholly owned subsidiary in Israel. Mycapssa and TPE are registered trademarks of Chiasma.
Sharon Merrill Associates